Autologous stem cell transplantation for patients with favorable- and intermediate-risk acute myeloid leukemia in first complete remission

Status

Active, not recruiting

Phases

Phase 3

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OCH-12002643

Enrollment

Unknown

Registered

2012-10-31

Start date

2008-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia

Interventions

Favorable-risk AML:Autologous stem cell transplantation

Intermediate-risk AML:Autologous stem cell transplantation

Eligibility

Sex/Gender

Male

Age

8 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients with de novel AML in favorable and intermediate-risk group younger than 60 years old; 2. Peripheral blood stem cell harvesting was started if patients reached CR1 and MRD level was less than 0.1% without LAIPs after 1 to 2 courses of induction therapy and at least 2-3 courses of consolidation therapy including high-doses Ara-C; 3. ECOG=0,1.

Exclusion criteria

Exclusion criteria: 1.Secondary AML, >60 years old; 2.AML in high-risk cytogenetic group; 3. to reach CR1 with more than 2 courses of induction; 4. >CR1 or MRD level >0.1% (including RQ-PCR test )and with FCM-LAIPs; 5.ECOG >=2.

Design outcomes

Primary

Measure	Time frame
Relaose-free survival;Overall survival (OS);	—

Secondary

Measure	Time frame
association between MRD and relapse;safety of ASCT;Factors associated with relapse;	—

Countries

China

Contacts

Public ContactXiao-jun Huan

huangxiaojun@bjmu.edu.cn+86 10 88326006

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026